Ben Tre Pharmaceutical JSC
HHOSE:DBT13,150.00
VND
0.00
(0.00%)
ISIN
VN000000DBT6
Return %
Stock
S&P 500
1Y
14.35
14.20
3Y
32.57
81.12
5Y
-1.15
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Trieu Thu Pham
- Full Time Employees
- 683
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Ben Tre Vietnam
- IPO Date
- Oct 30, 2009
- Website
- bepharco.com
- Similar Companies
- Business
- Ben Tre Pharmaceutical Joint Stock Company (Bepharco, HOSE: DBT) is a Vietnam-based healthcare enterprise engaged in the manufacturing, importing, marketing, and nationwide distribution of pharmaceutical products, active healthcare supplements, and medical supplies. Founded in 1963 and headquartered in Ben Tre City, Ben Tre Province, Vietnam, with executive management offices in Ho Chi Minh City, the company operates an integrated pharmaceutical value chain serving both public and private hospitals, healthcare clinics, commercial drugstore chains, and independent retail pharmacies across all major regions of Vietnam. The company offers an extensive portfolio of prescription (Rx) pharmaceuticals, over-the-counter (OTC) medicines, traditional herbal preparations, and consumer healthcare products, structured across systematic therapeutic and commercial categories, including: anti-infective medications, antibiotics, antifungals, and antivirals; central nervous system and cardiovascular agents; respiratory, gastrointestinal, and hepatobiliary formulations; probiotic and digestive health treatments, notably the EnteroGolds product line; traditional and herbal medications, led by the proprietary Cam Xuyen Huong cold and flu remedy series; vitamins, multivitamin complexes, minerals, and functional dietary supplements; obstetrics, gynecology, and maternal health therapeutics; sterile injectables, intravenous infusions, topical dermatological ointments, and medicinal syrups; and the wholesale distribution and logistics of imported specialized pharmaceuticals, diagnostic reagents, and medical consumables. Bepharco executes its manufacturing and commercial operations through WHO-GMP certified production facilities alongside consolidated subsidiaries and affiliates, including Yen Bai Pharmaceutical Joint Stock Company (Ypharco), which focuses on herbal and traditional medicine processing, Nha Trang Vaccine and Biological Products Joint Stock Company (Biopharco), and BHC Pharmaceutical Joint Stock Company, established to expand specialized healthcare product supply. In recent strategic developments, the company refreshed its corporate brand identity and logo, completed governance restructuring with the election of a new Board of Directors for the 2024–2029 term, and expanded international supply partnerships with multinational pharmaceutical manufacturers such as Gedeon Richter, Egis Pharmaceuticals, Meditop, and AFT Pharmaceuticals. Additionally, Bepharco has continued strategic capital investments aimed at upgrading its manufacturing infrastructure toward EU-GMP and Japan-GMP equivalent standards to strengthen its competitive positioning in domestic public hospital tender channels and expand regional export capabilities.